Agreement reached on EU's new pharma legislation Agreement has been reached on the reform of EU pharma legislation, but industry thinks it does not go far enough to restore the bloc's global status.

The #EU Council and Parliament have reached an #agreement in principle on the long-awaited #pharmareform package, but Europe's drug industry has already said it will not be enough to keep the sector competitive.

Brevetti farmaceutici e il patto faustiano dell’Europa moderna La riforma dei brevetti farmaceutici UE: tra diritti, interessi e salute pubblica. Scopri perché l’Europa rischia di sacrificare l’accesso ai farmaci.

Can we accept that health, a fundamental right, is tied to numbers and market strategies? The EU’s pharmaceutical reform risks prioritizing profits over access, leaving many in the shadows. #HealthForAll #PharmaReform

Congrats to Reshma Ramachandran MD, MPP, MHS (Yale NCSP '20–'22), winner of the 2025 Bernard Lown Award for Social Responsibility! 👏 A powerful voice for health equity. Learn More: bit.ly/reshma-lown2025
#HealthEquity #SocialResponsibility #YaleNCSP #PharmaReform #PublicHealth@reshmagar.bsky.social

The NIH spent $100B+ on research behind every FDA-approved drug from 2010–2016—yet taxpayers get no return. Pharma profits off public risk. We need revenue-sharing, price protections, or a public option. Taxpayers shouldn’t pay twice. #PublicReturnOnPublicInvestment #PharmaReform

"Unpacking the Global Health side effects of the EU's pharmaceutical legislation reform": the 3rd #EGHRIN Seminar will take place online on December 5th, 14:00-15:00 CET, with three outstanding speakers.
Register at aighd.zoom.us/meeting/regi...
#GlobalHealth #EUPolicy #PharmaReform #EGHRIN